Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roivant Sciences Ltd.

http://roivant.com

Latest From Roivant Sciences Ltd.

Deal Watch: Roche Partners With Dyno On AAV-Delivered Gene Therapies

Also, deals between Boehringer Ingelheim/Oxford BioTherapeutics, Bausch/Eyenovia, Ligand/HitGen, Moderna/Merck & Co., Vincera/Bayer, Genentech/Kineta, Selecta/IGAN, RedHill/AstraZeneca, Urovant/Sunovion, Biogen/Scribe, BridgeBio/Eidos, Elevar/Taiba

Deals Business Strategies

Poxel’s Phase II Data Add AMP Kinase Activation To NASH Possibilities

Recent development upheaval in non-alcoholic steatohepatitis has created opportunity for new approaches, and Poxel thinks its AMPK activator may address several NASH-related pathologies.

Clinical Trials Drug Approval Standards

Dermavant's Tapinarof Could Bring Innovation To Topical Psoriasis Market

CEO Todd Zavodnick said the non-steroidal topical cream is poised to become a blockbuster brand.

Dermatology Clinical Trials

Finance Watch: 2020 Cell And Gene Therapy Funding Already Bests 2019

Private Company Edition: The Alliance for Regenerative Medicine’s half-year report shows the sector raised $10.7bn in the first half of 2020 versus $9.8bn raised in all of 2019. Also, DCVC Bio closed a $350m fund, new incubator opportunities and VC mega-deals for Dyne and Atomwise.

Financing Innovation
See All

Company Information

UsernamePublicRestriction

Register